CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a low-cost method to analyze tumor genomic material from exosomes in metastatic prostate cancer. By integrating this analysis with other non-invasive techniques, the goal is to identify prognostic signatures and predictive markers for treatment response, ultimately enhancing personali…
Metastatic prostate cancer (mPC) is a lethal disease.
Androgen deprivation therapy is the mainstay of patient care.
In addition, DNA repair defects is a novel therapeutic target in mPC.
However, resistances invariably arise, triggered most of the times by tumor genomic evolution.
Liquid biopsy has emerged as a tool to non-invasively profile tumor genomics over time.
Beyond circulating tumor DNA (ctDNA) and circulating tumor cells (CTC), small extracellular vesicles, known as exosomes, have been…
FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
